middle.news
How Will Optiscan’s $17.75m Raise Accelerate Its FDA Approval Journey?
9:43am on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
How Will Optiscan’s $17.75m Raise Accelerate Its FDA Approval Journey?
9:43am on Tuesday 28th of October, 2025 AEDT
Key Points
Raised $17.75 million via fully underwritten entitlement offer
Initiated breast cancer clinical study at Royal Melbourne Hospital
Advanced international clinical trials including veterinary and GI studies
Ongoing preparations for US FDA premarket approval submissions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Optiscan Imaging (ASX:OIL)
OPEN ARTICLE